Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Dermatology

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    August 2019
  1. SCHVARTSMAN G, Ma J, Bassett RL Jr, Haydu LE, et al
    Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32454.
    PubMed     Text format     Abstract available



  2. Erratum: Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18-44.
    Cancer. 2019;125:2706.
    PubMed     Text format    


    July 2019
  3. LEE CT, Lehrer EJ, Aphale A, Lango M, et al
    Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients.
    Cancer. 2019 Jul 29. doi: 10.1002/cncr.32371.
    PubMed     Text format     Abstract available


  4. RULLI E, Legramandi L, Salvati L, Mandala M, et al
    The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32375.
    PubMed     Text format     Abstract available


    May 2019
  5. NAJJAR YG, Puligandla M, Lee SJ, Kirkwood JM, et al
    An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32162.
    PubMed     Text format     Abstract available


    February 2019
  6. PRINTZ C
    Skin cancer prevention advocates target indoor tanning: As tanning beds increasingly turn up outside of traditional salons, experts are trying innovative approaches to curb their use.
    Cancer. 2019;125:493-494.
    PubMed     Text format    


    January 2019
  7. GIBNEY GT, Atkins MB
    Choice of first-line therapy in metastatic melanoma.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31774.
    PubMed     Text format    


  8. OTT PA, Pavlick AC, Johnson DB, Hart LL, et al
    A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31892.
    PubMed     Text format     Abstract available


    December 2018
  9. APPENZELLER S, Gesierich A, Thiem A, Hufnagel A, et al
    The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31843.
    PubMed     Text format     Abstract available


  10. CHAN AA, Noguti J, Pak Y, Qi L, et al
    Interaction of body mass index or waist-to-hip ratio and sun exposure associated with nonmelanoma skin cancer: A prospective study from the Women's Health Initiative.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31810.
    PubMed     Text format     Abstract available


  11. SAAB KR, Mooradian MJ, Wang DY, Chon J, et al
    Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31889.
    PubMed     Text format     Abstract available


    November 2018
  12. BHATTY M, Kato S, Piha-Paul SA, Naing A, et al
    Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies.
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31812.
    PubMed     Text format     Abstract available


    October 2018

  13. Older melanoma patients may respond better to anti-PD1 immunotherapy.
    Cancer. 2018;124:3961.
    PubMed     Text format    


  14. TARHINI AA, Frankel P, Ruel C, Ernstoff MS, et al
    NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31734.
    PubMed     Text format     Abstract available


  15. JETER JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, et al
    Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials.
    Cancer. 2018 Oct 3. doi: 10.1002/cncr.31719.
    PubMed     Text format     Abstract available


    September 2018
  16. GOLDSTEIN AM, Stidd KC, Yang XR, Fraser MC, et al
    Pediatric Melanoma in Melanoma-Prone Families.
    Cancer. 2018 Sep 12. doi: 10.1002/cncr.31641.
    PubMed     Text format     Abstract available


    July 2018
  17. FAJE AT, Lawrence D, Flaherty K, Freedman C, et al
    High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31629.
    PubMed     Text format     Abstract available


    April 2018
  18. DAVIS EJ, Johnson DB, Sosman JA, Chandra S, et al
    Melanoma: What do all the mutations mean?
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31345.
    PubMed     Text format     Abstract available


    March 2018
  19. GOLD KA, Kies MS, William WN Jr, Johnson FM, et al
    Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31346.
    PubMed     Text format     Abstract available


  20. TSAI KK, Bollin KB, Patel SP
    Obstacles to improving outcomes in the treatment of uveal melanoma.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31284.
    PubMed     Text format     Abstract available


  21. PRINTZ C
    First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Cancer. 2018;124:1097-1098.
    PubMed     Text format    


  22. LEHRER S, Rheinstein PH, Rosenzweig KE
    Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31262.
    PubMed     Text format    


  23. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
    Cancer. 2018 Mar 15. doi: 10.1002/cncr.31261.
    PubMed     Text format    


    January 2018
  24. SHURELL E, Olcese C, Patil S, McCormick B, et al
    Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
    Cancer. 2018;124:46-54.
    PubMed     Text format     Abstract available


    December 2017
  25. ARUN BK, Gutierrez Barrera AM, Ueno NT
    Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31188.
    PubMed     Text format    


  26. ALTUNDAG K
    Diagnosis of patients with inflammatory breast cancer is a problematic issue.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31189.
    PubMed     Text format    


  27. MILLER JW, Smith JL, Ryerson AB, Tucker TC, et al
    Disparities in breast cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5100-5118.
    PubMed     Text format     Abstract available


  28. ROSENSTOCK AS, Niu J, Giordano SH, Zhao H, et al
    Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Cancer. 2017 Dec 13. doi: 10.1002/cncr.31144.
    PubMed     Text format     Abstract available


  29. OHRI N, Haffty BG, Buchholz TA
    The role of postmastectomy radiotherapy in patients with stage II breast cancer.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31130.
    PubMed     Text format    


  30. NIXON NA, Khan OF, Imam H, Tang PA, et al
    Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Cancer. 2017;123:4672-4679.
    PubMed     Text format     Abstract available


    November 2017
  31. MANNEVILLE F, Rotonda C, Conroy T, Bonnetain F, et al
    The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.
    Cancer. 2017 Nov 8. doi: 10.1002/cncr.31108.
    PubMed     Text format     Abstract available


  32. OHRI N, Sittig MP, Tsai CJ, Hwang ES, et al
    Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31080.
    PubMed     Text format     Abstract available


  33. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Text format     Abstract available


    October 2017
  34. WALLACE AS, Keene KS, Williams CP, Jackson BE, et al
    Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.30989.
    PubMed     Text format     Abstract available


  35. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    PubMed     Text format     Abstract available


  36. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    PubMed     Text format     Abstract available


  37. GUTIERREZ BARRERA AM, Fouad TM, Song J, Webster R, et al
    BRCA mutations in women with inflammatory breast cancer.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31069.
    PubMed     Text format     Abstract available


  38. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available


  39. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Text format     Abstract available


  40. DONALDSON AR, McCarthy C, Goraya S, Pederson HJ, et al
    Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31061.
    PubMed     Text format     Abstract available


  41. JAGSI R, Abrahamse PH, Lee KL, Wallner LP, et al
    Treatment decisions and employment of breast cancer patients: Results of a population-based survey.
    Cancer. 2017 Oct 9. doi: 10.1002/cncr.30959.
    PubMed     Text format     Abstract available


  42. ARLEO EK, Hendrick RE, Helvie MA, Sickles EA, et al
    Comparison of recommendations for screening mammography using CISNET models.
    Cancer. 2017;123:3673-3680.
    PubMed     Text format     Abstract available


    September 2017
  43. CHAOUL A, Milbury K, Spelman A, Basen-Engquist K, et al
    Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.30938.
    PubMed     Text format     Abstract available


  44. HARTMAN SJ, Nelson SH, Myers E, Natarajan L, et al
    Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study.
    Cancer. 2017 Sep 19. doi: 10.1002/cncr.30987.
    PubMed     Text format     Abstract available


  45. NGUYEN KH, Pasick RJ, Stewart SL, Kerlikowske K, et al
    Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups.
    Cancer. 2017;123:3468-3475.
    PubMed     Text format     Abstract available


  46. KAROL SE, Yang W, Smith C, Cheng C, et al
    Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.
    Cancer. 2017;123:3602-3608.
    PubMed     Text format     Abstract available


  47. STURGEON KM, Hackley R, Fornash A, Dean LT, et al
    Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30935.
    PubMed     Text format     Abstract available


    August 2017
  48. SENNERSTAM RB, Franzen BSH, Wiksell HOT, Auer GU, et al
    Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.
    Cancer. 2017 Aug 24. doi: 10.1002/cncy.21909.
    PubMed     Text format     Abstract available


  49. MASTELLARO MJ, Seidinger AL, Kang G, Abrahao R, et al
    Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
    Cancer. 2017;123:3150-3158.
    PubMed     Text format     Abstract available


  50. MARMOR S, Hui JYC, Huang JL, Kizy S, et al
    Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Cancer. 2017;123:3015-3021.
    PubMed     Text format     Abstract available


  51. HAWLEY ST, Griffith KA, Hamilton AS, Ward KC, et al
    The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients.
    Cancer. 2017 Aug 15. doi: 10.1002/cncr.30924.
    PubMed     Text format     Abstract available


  52. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available


  53. VAZ-LUIS I, O'Neill A, Sepucha K, Miller KD, et al
    Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
    Cancer. 2017;123:2821-2828.
    PubMed     Text format     Abstract available


    July 2017
  54. POWIS M, Sutradhar R, Gonzalez A, Enright KA, et al
    Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30804.
    PubMed     Text format     Abstract available


    June 2017
  55. TARAZI WW, Bradley CJ, Bear HD, Harless DW, et al
    Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment.
    Cancer. 2017 Jun 26. doi: 10.1002/cncr.30771.
    PubMed     Text format     Abstract available


  56. WALLNER LP, Li Y, McLeod MC, Hamilton AS, et al
    Decision-support networks of women newly diagnosed with breast cancer.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30848.
    PubMed     Text format     Abstract available


  57. ABRAHAMS HJG, Gielissen MFM, Donders RRT, Goedendorp MM, et al
    The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30815.
    PubMed     Text format     Abstract available


    May 2017
  58. KOROUKIAN SM, Bakaki PM, Htoo PT, Han X, et al
    The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio's underserved women.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30720.
    PubMed     Text format     Abstract available


  59. BROWNE JP, Jeevan R, Gulliver-Clarke C, Pereira J, et al
    The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer.
    Cancer. 2017 May 17. doi: 10.1002/cncr.30788.
    PubMed     Text format     Abstract available


  60. PRINTZ C
    Genomic sequencing of treatment-resistant metastatic breast cancer reveals key alterations.
    Cancer. 2017;123:904.
    PubMed     Text format    


  61. PRINTZ C
    Artificial intelligence platform for oncology could assist in treatment decisions.
    Cancer. 2017;123:905.
    PubMed     Text format    


    April 2017
  62. HSU CD, Wang X, Habif DV Jr, Ma CX, et al
    Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.
    Cancer. 2017 Apr 25. doi: 10.1002/cncr.30722.
    PubMed     Text format     Abstract available


  63. KATZ SJ, Wallner LP, Abrahamse PH, Janz NK, et al
    Treatment experiences of Latinas after diagnosis of breast cancer.
    Cancer. 2017 Apr 11. doi: 10.1002/cncr.30702.
    PubMed     Text format     Abstract available


  64. LIANG X, Margolis KL, Hendryx M, Reeves K, et al
    Effect of depression before breast cancer diagnosis on mortality among postmenopausal women.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30688.
    PubMed     Text format     Abstract available


  65. CASSIDY RJ, Liu Y, Kahn ST, Jegadeesh NK, et al
    The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30675.
    PubMed     Text format     Abstract available


  66. PRINTZCANCER C
    Breast cancer mortality rates decline internationally, with some major exceptions.
    Cancer. 2017;123:1085.
    PubMed     Text format    


  67. PRINTZCANCER C
    Study to examine genetic factors behind increased risk of breast cancer in African Americans.
    Cancer. 2017;123:1083-1084.
    PubMed     Text format    


    March 2017
  68. HENRY NL, Braun TM, Breslin TM, Gorski DH, et al
    Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30674.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: